Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 12/20 | 0.92 |
| ▸ | ATP1B1 | P05026 | 12/20 | 0.92 |
| ▸ | ATP1A3 | P13637 | 12/20 | 0.92 |
| ▸ | ATP1B2 | P14415 | 12/20 | 0.92 |
| ▸ | ATP1A2 | P50993 | 12/20 | 0.92 |
| ▸ | ATP1B3 | P54709 | 12/20 | 0.92 |
| ▸ | FXYD2 | P54710 | 12/20 | 0.92 |
| ▸ | ATP1A4 | Q13733 | 12/20 | 0.92 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | HBB | P68871 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 1/20 | 0.62 |
| ▸ | SLCO4C1 | Q6ZQN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digitoxigenin Gentiobioside SCHEMBL1652279 | 1.00 | ATP1A1 (0.92) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Uzarin SCHEMBL702463 | 1.00 | ATP1A1 (0.92) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Desglucouzarin SCHEMBL30615298 | 0.96 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Thevetin B SCHEMBL869661 | 0.93 | ATP1A1 (0.80) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Thevetin B SCHEMBL29463277 | 0.93 | ATP1A1 (0.80) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Thevetin B SCHEMBL29389027 | 0.93 | ATP1A1 (0.80) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Thevetin B SCHEMBL12556692 | 0.93 | ATP1A1 (0.80) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL29413165 | 0.93 | ATP1A1 (0.79) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL31655532 | 0.91 | ATP1A1 (0.91) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL31135096 | 0.91 | ATP1A1 (0.91) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791079-B2 | Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-29 | — | — | US | claimed |
| WO-2010104998-A2 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (MNCE) | JOHNS HOPKINS UNIVERSITY (US) | 2010-09-16 | — | — | WO | claimed |
| EP-1539099-A4 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS LLC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | AZAYA THERAPEUTICS, INC. | 2006-09-14 | — | — | US | claimed |
| US-6986901-B2 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-17 | — | — | US | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | MCNEIL-PPC, INC | 2005-06-23 | — | — | US | claimed |
| EP-1539099-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | Lyotropic Therapeutics, LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1531801-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004006902-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006901-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040013741-A1 | Gastrointestinal compositions | JOHNSON & JOHNSON CONSUMER INC. | 2004-01-22 | — | — | US | claimed |
| US-20040010035-A1 | Gastrointestinal compositions | MCNEIL-PPC, INC | 2004-01-15 | — | — | US | claimed |
| US-20040010034-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| US-20040009234-A1 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY | 2004-01-15 | — | — | US | claimed |
| WO-2003106382-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | DSG1, PDIA5, NISCH | ATP1A1 2112/4885ATP1B1 1353/4885ATP1A3 1132/4885 |
| US-20040010034-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ATP1A1 678/4885ATP1B1 1312/4885ATP1A3 474/4885 |
| US-20040013741-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ATP1A1 678/4885ATP1B1 1312/4885ATP1A3 474/4885 |
| US-20040009234-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ATP1A1 678/4885ATP1B1 1312/4885ATP1A3 474/4885 |
| US-20040010035-A1 | Gastrointestinal compositions | FABP2, SLC10A2, FABP6 | ATP1A1 678/4885ATP1B1 1312/4885ATP1A3 474/4885 |
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | SLC8B1, ATP2A1, ATP2A2 | ATP1A1 109/4885ATP1B1 166/4885ATP1A3 95/4885 |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | HTR4, HTR6, SLC6A4 | ATP1A1 817/4885ATP1B1 721/4885ATP1A3 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.